Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48.

Article  PubMed  PubMed Central  Google Scholar 

Pölönen P, Mullighan CG, Teachey DT. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood. 2024. https://doi.org/10.1182/blood.2023022920.

Article  PubMed  Google Scholar 

Rheingold SR, Bhojwani D, Ji L, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a children’s oncology group study. Leukemia. 2024. https://doi.org/10.1038/s41375-024-02395-4.

Article  PubMed  PubMed Central  Google Scholar 

Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):e142–54.

Article  PubMed  PubMed Central  Google Scholar 

Ribera JM, Morgades M, Genescà E, et al. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematol Oncol. 2021;39(4):529–38.

Article  CAS  PubMed  Google Scholar 

O’Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186–91.

Article  PubMed  Google Scholar 

Shah B, Mattison RJ, Abboud R, et al. acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22(8):563–76.

Article  Google Scholar 

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric acute lymphoblastic leukemia. Version 1. 2025. Plymouth Meeting, PA: National Comprehensive Cancer Network. 2024. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1496

Hematology Oncology Committee, Chinese Anti-Cancer Association; Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024). Chin J Hematol. 2024;45(5):417–29. https://doi.org/10.3760/cma.j.cn121090-20240319-00102. (In Chinese).

Article  Google Scholar 

Hematological Oncology Committee of China Anti-Cancer Association; Chinese Society of Hematology, Chinese Medical Association; Chinese Working Group for T Cell Lymphoma, Hematological Oncology Committee of China Anti-Cancer Association. The consensus of the diagnosis and treatment of adult T-cell lymphoblastic lymphoma in China (2023). Chin J Hematol. 2023;44(5):353–8. https://doi.org/10.3760/cma.j.issn.0253-2727.2023.05.001. (In Chinese).

Article  Google Scholar 

The Society of Blood Disease Translational Medicine of China Anti-Cancer Association; Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association; Hematology Committee of China Medical Women’s Association. Chinese expert consensus on diagnosis and treatment of adult early T cell precursor acute lymphoblastic leukemia (2023). Chin J Hematol. 2023;44(12):977–82. https://doi.org/10.3760/cma.j.issn.0253-2727.2023.12.002. (In Chinese).

Article  Google Scholar 

Guo W, Cao Y, Liu J, et al. Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study. Bone Marrow Transpl. 2023;58(10):1163–6.

Article  CAS  Google Scholar 

Xue SL, Cui HX, Zou JY, et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. Hematol Oncol. 2013;31(4):206–12.

Article  CAS  PubMed  Google Scholar 

Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2015;39(3):323–8.

Article  CAS  PubMed  Google Scholar 

Li X, Liu L, Zhang Y, et al. Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2015;39(11):1201–6.

Article  CAS  Google Scholar 

Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599–608.

Article  CAS  PubMed  Google Scholar 

He H, Wen X, Zheng H. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology. 2024;29(1):2343604.

Article  PubMed  Google Scholar 

Richard-Carpentier G, Jabbour E, Short NJ, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-Cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212–8.

Article  PubMed  Google Scholar 

Arora S, Vachhani P, Bachiashvili K, Jamy O. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(9):2292–4.

Article  CAS  PubMed  Google Scholar 

Kong J, Chen N, Li M, et al. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol. 2022;101(3):697–9.

Article  CAS  PubMed  Google Scholar 

Wan CL, Zou JY, Qiao M, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62(13):3300–3.

Article  PubMed  Google Scholar 

Qian JJ, Hu X, Wang Y, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med. 2020;9(15):5327–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meng T, Yao Y, Xu Y, et al. Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2020;38(5):834–7.

Article  CAS  PubMed  Google Scholar 

Horinaka M, Yoshida T, Nakata S, et al. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. Cancer Sci. 2012;103(2):282–7.

Article  CAS  PubMed  Google Scholar 

Suo S, Zhao D, Li F, et al. Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia. Blood. 2024;144(12):1343–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin Z, Gao Y, Bu X, et al. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis. Leuk Lymphoma. 2024. https://doi.org/10.1080/10428194.2024.2400228.

Article  PubMed  Google Scholar 

Suo S, Sun S, Nguyen LXT, et al. Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: bench and bed. Med. 2024. https://doi.org/10.1016/j.medj.2024.07.018.

Article  PubMed  Google Scholar 

Yin Z, Yao Z, Chen D, et al. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. J Cancer Res Clin Oncol. 2024;150(7):336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai Y, Luo L, Wei Z, Cheng P, Luo J, Li J. The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience. Ann Hematol. 2024. https://doi.org/10.1007/s00277-024-05892-9.

Article  PubMed  PubMed Central  Google Scholar 

Bhatla T, Hogan LMD, Teachey DT, et al. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: DELPHINUS study. Blood. 2024. https://doi.org/10.1182/blood.2024024493.

Article  PubMed  Google Scholar 

Bader MS, Kubetzko S, Schäfer BW, et al. Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2024;103(11):4831–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aygüneş U, Karagün BŞ, Şaşmaz I, Antmen AB. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: a single-center experience. Clin Transpl. 2024;38(5):e15366. 

Article